葡萄膜炎藥物市場規模、佔有率和成長分析（按疾病類型、治療類型、病因、給藥途徑、配銷通路、適應症和地區）- 行業預測 2025-2032

2023 年全球葡萄膜炎藥物市場規模價值7.58 億美元，預計將從2024 年的8.0879 億美元成長至2032 年的13.5878 億美元，預計在預測期內（2025-2036 年）到2032 年將達到13.5878 億美元)。

由於研發活動的活性化，眼科市場正在強勁擴張。針對眼部炎症，特別是難治性後葡萄膜炎和中間葡萄膜炎的臨床試驗在世界各地正在增加。目前的 III 期試驗正在評估Mycophenolate Mofetil和胺基甲基葉酸等創新治療方法，這些療法被定位為非感染性葡萄膜炎標準皮質類固醇治療的替代品。此外，廣泛的研究和開發努力促進了生物藥品的發展，增強了眼部發炎疾病的治療方法。這種發展不僅使治療選擇多樣化，而且刺激了對這些創新療法的需求增加，從而推動了眼科領域整體市場的成長。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步

葡萄膜炎治療藥物市場規模（依疾病類型）

• 市場概況
• 前葡萄膜炎
• 後葡萄膜炎
• 中間葡萄膜炎
• 葡萄膜炎

葡萄膜炎治療藥物市場規模（依治療類型）

• 市場概況
• 皮質類固醇
• 免疫抑制劑
• 單株抗體
• 睫狀肌麻痺藥物
• 抗生素
• 抗病毒藥物
• 抗真菌
• 止痛藥

葡萄膜炎治療市場規模（按原因）

• 市場概況
• 感染
• 非感染性

葡萄膜炎治療藥物市場規模（依給藥途徑）

• 市場概況
• 局部的
• 全身
• 注射
• 玻璃體內

葡萄膜炎治療藥物市場規模（依分銷管道）

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局
• 其他

葡萄膜炎治療藥物市場規模（依適應症）

• 市場概況
• 前葡萄膜炎
• 中間葡萄膜炎
• 後葡萄膜炎
• 葡萄膜炎

葡萄膜炎治療藥物的市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• AbbVie Inc.（United States）
• Novartis AG（Switzerland）
• Bausch Health Companies Inc.（Canada）
• EyePoint Pharmaceuticals, Inc.（United States）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Alimera Sciences, Inc.（United States）
• Clearside Biomedical, Inc.（United States）
• Eyegate Pharmaceuticals, Inc.（United States）
• Horizon Therapeutics Plc（Ireland）
• Mylan NV（United States）
• Sun Pharmaceutical Industries Ltd.（India）
• Regeneron Pharmaceuticals, Inc.（United States）
• Merck & Co., Inc.（United States）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Pfizer Inc.（United States）
• Amgen Inc.（United States）
• Sanofi（France）
• Galapagos NV（Belgium）
• Tarsier Pharma Ltd.（Israel）
• TopiVert Ltd.（United Kingdom）

結論和建議

Global Uveitis Treatment Market size was valued at USD 758.0 million in 2023 and is poised to grow from USD 808.79 million in 2024 to USD 1358.78 million by 2032, growing at a CAGR of 6.7% during the forecast period (2025-2032).

The ophthalmology market is witnessing a robust expansion fueled by intensified research and development activities. A growing number of clinical trials are underway globally, targeting eye inflammation issues, particularly refractory posterior and intermediate uveitis. Current phase III trials are assessing innovative therapies like mycophenolate mofetil and methotrexate, which are being positioned as alternatives to standard corticosteroid treatments for noninfectious uveitis. Moreover, advancements in the development of biological drugs through extensive R&D efforts have enriched the therapeutic landscape for eye inflammation disorders. This evolution is not only diversifying treatment options but also spurring heightened demand for these innovative therapies, thereby propelling overall market growth in the field of ophthalmology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Uveitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Uveitis Treatment Market Segmental Analysis

Global Uveitis Treatment Market is segmented by Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication and region. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Treatment Type, the market is segmented into Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal and Analgesics. Based on Cause, the market is segmented into Infectious and Non-infectious. Based on Route of Administration, the market is segmented into Topical, Systemic, Injectable and Intravitreal. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Indication, the market is segmented into Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis and Panuveitis. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Uveitis Treatment Market

The global uveitis treatment market is primarily driven by the rising incidence and prevalence of uveitis across the globe, fueled by factors such as autoimmune diseases, infections, and inflammatory conditions. The introduction of innovative treatment options, including biologic therapies, immunosuppressants, and targeted therapies, has greatly enhanced the management of this condition, leading to more effective and specific treatment modalities. Additionally, heightened awareness surrounding uveitis among healthcare professionals and patients has facilitated earlier diagnoses and prompt treatment, further increasing the demand for various uveitis treatment options. These elements collectively contribute to the robust growth of the uveitis treatment market.

Restraints in the Global Uveitis Treatment Market

Global Uveitis Treatment faces significant challenges including limited access to healthcare facilities and specialized care in low-resource settings, contributing to disparities in diagnosis and management across regions. The diversity in underlying causes of uveitis, ranging from infectious to autoimmune and idiopathic origins, complicates standardized treatment protocols. Additionally, varying levels of awareness and education among healthcare providers can lead to mismanagement or delayed treatment. Economic constraints, coupled with the availability of medications, further restrict effective treatment options. Therefore, addressing these barriers necessitates a coordinated global effort to improve access to education, resources, and healthcare infrastructure for uveitis management globally.

Market Trends of the Global Uveitis Treatment Market

The Global Uveitis Treatment market is witnessing significant trends driven by innovation and personalized medicine. There is an accelerated development of targeted therapies, particularly biologics and immunomodulatory drugs, enhancing the management of inflammation in uveitis patients. The adoption of sustained-release drug delivery systems, such as intravitreal implants, is growing, facilitating prolonged drug action and minimizing injection frequency. Furthermore, personalized medicine is gaining traction as genetic and molecular profiling offers tailored treatment strategies. Collaborations between pharmaceutical firms and research institutions are fostering the creation of novel therapies, while the infusion of advanced technologies like AI and telemedicine is revolutionizing patient monitoring and management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Uveitis Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis

Global Uveitis Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Corticosteroids
• Immunosuppressant
• Monoclonal Antibodies
• Cycloplegic Agents
• Antibiotics
• Antivirals
• Antifungal
• Analgesics

Global Uveitis Treatment Market Size by Cause & CAGR (2025-2032)

• Market Overview
• Infectious
• Non-infectious

Global Uveitis Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Topical
• Systemic
• Injectable
• Intravitreal

Global Uveitis Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Uveitis Treatment Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Anterior Uveitis
• Intermediate Uveitis
• Posterior Uveitis
• Panuveitis

Global Uveitis Treatment Market Size & CAGR (2025-2032)

• North America (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eyegate Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galapagos NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tarsier Pharma Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TopiVert Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations